Of the four major strains of the influenza virus, A and B cause most human illness and the annual flu epidemics, novel A subtypes can even result in pandemics (e.g. H1N1 for the 1918 flu pandemic) and are responsible for most severe cases and deaths. [1]
A new universal vaccine against the influenza A virus was tested successfully on mice and ferrets. It conferred protection against multiple distinct influenza A strains in mice and ferrets. [2]
A Phase 1 clinical trial of a candidate vaccine, BPL-1357 has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The placebo-controlled trial will test the safety and its ability to prompt immune responses. [3] It is scheduled to complete on 1 March 2023, and will generate evidence for safety and Immunogenicity against various strains. [4]